Objectives: The purpose of this study was to investigate the effects of gene transfection of endothelial cells with vascular endothelial growth factor (VEGF) on re-endothelialization and inhibiting in-stent restenosis. Methods: Stents coated with human umbilical vein endothelial cells (HUVECs) transfected with VEGF 121 were studied both in vitro and in vivo. In vitro studies were performed using a homemade extracorporeal circulation system. In vivo studies were performed using the rabbit abdominal aorta model. 
The integrity and functional activity of the endothelial monolayer play a crucial role in the prevention of thrombosis and in-stent restenosis (ISR). A growing body of evidence suggests that drugs loaded on drug-eluting stents could impair the healing process of the injured arterial wall and lead to delayed re-endothelialization. 1, 2 The molecular mechanism is established with cell-cycle regulators 3 and endothelial vasomotor factor in endothelial cells (ECs). 4 Moreover, drugs may also impair the circulation of endothelial progenitor cells for re-endothelialization in vivo. 5 It has been reported that drugs loaded on drug-eluting stents inhibit proliferation, migration, differentiation, and the endothelial nitric oxide synthase (eNOS) production in human endothelial progenitor cells. 6, 7 Therefore, confluent endothelialization of the stent in vitro before implantation is proposed as an improved procedure to reduce complications of stent implantation, including thrombosis and ISR.
Vascular endothelial growth factor (VEGF) is a potent endothelium-specific angiogenic factor, which promotes re-endothelialization of the denuded arterial wall. 8 Recombinant VEGF has been administered in animal models of arterial injury. Further studies with VEGF-coated stents have suggested that increased re-endothelialization reduces restenosis and inhibits stent thrombosis. [9] [10] [11] Other endothelial mitogens like basic fibroblast growth factor, 12 platelet-derived growth factor, 13 and eNOS 14 have led to testing the hypothesis that gene therapy-mediated acceleration of endothelial recovery is an alternative strategy for prevention of neointima proliferation.
However, gene therapeutic approach at a targeted site of arterial injury is commonly limited by a low transfection efficiency resulting from many factors, such as abrasion of the endothelial layer. 15 Therefore, utilizing transfected cells may increase the expression of genes and develop an emerging strategy for arterial gene delivery. In this study, we used VEGF 121 -transfected human umbilical vein endothelial cells (HUVECs) as seeding cells on stents and examined their efficiencies on re-endothelialization in vitro and suppressing restenosis after implantation in the rabbit abdominal aorta model.
MATERIALS AND METHODS
Culture and identification of human umbilical vein endothelial cells. HUVECs (a generous gift from Dr Lushan Liu, Nan Hua University, China) in endothelial basal media (RPMI 1640; HyClone USA, Logan, Utah) supplemented with 10% fetal calf serum (FCS; Cambrex Corp, Charles City, Iowa) and antibiotic/antimycotics solution (Gibco Industries Inc, Langley, Okla) were grown to confluence in T-75 polystyrene flasks (Becton Dickinson and Company, Franklin Lakes, NJ). Cells were cultured in a CO 2 incubator (5% CO 2 ) at 37°C. HUVECs were identified by means of morphology observation (Fig 1, a) , and immunohistochemistry of CD31 (Platelet-endothelial cell adhesion molecule-1 [PECAM-1/CD31]) (Fig 1, b; Carlsbad, Calif) according to our previously reported methods. 16 Briefly, HUVECs were seeded (2 ϫ 10 5 cells per 35-mm well) on plates and grown in RPMI 1640 medium supplemented with 10% FCS for 24 hours. Cells were then washed three times with phosphate-buffered saline (PBS; Hyclone, Logan, Utah). A mixture for transfection was prepared by mixing plasmid pCD 2 -VEGF 121 with lipo2000 in medium for 15 to 40 minutes at room temperature. Transfection was then conducted by incubating cells in media containing the mixture at 37°C for 4 to 6 hours. The mammalian expression vectors pCD 2 -VEGF 121 can be used for generating stably transfected cell lines using a selection with geneticin (G418). The neomycin phosphotransferase (neo) cassette in the backbone of pCD 2 -VEGF 121 confers resistance to G418. In this study, transfected cells were screened with 700 g/mL of G418 (Amerisco, Solon, Ohio), in which condition nontransfected cells did not survive. After the screening procedure, transfected cells were cultured in medium containing G418 (200 g/mL).
Western blot (Fig 1, c) , reverse transcription-polymerase chain reaction (RT-PCR; Fig 1, d ) and immunohistochemistry (Fig 1, e and f) were used for the assessment of transfection efficiency. The exact sequences of the primers used for the VEGF 121 RT-PCR were as follows: 5=-GAGTACATCTTC AAG CCATCC TGTGTG-3= 5=-CGCCTCGGCTTGTCACAT TTTTCTTGT-3= Kit (Beyotime, China) was used to collect cell proteins and keep identical protein concentration in all samples. VEGF 121 expression in transfected cells was examined by Western blot, in which the primary polyclonal antibody against VEGF (Boster, China) and the horseradish peroxidase-signed secondary goat anti-rabbit IgG antibody (Beyotime, China) were selected, and ␤-actin was used as internal control. VEGF 121 expression was examined also by immunohistochemistry, in which the primary polyclonal antibody against VEGF (Boster, China) and the secondary goat anti-rabbit IgG antibody (Boster, China) were used. RT-PCR was applied to characterize the gene expression of VEGF 121 .
Cell seeding and detecting in vitro. We used 316L stainless steel stents (1.6 mm in diameter and 18 mm in length; Beijing Amsino Medical Co, Ltd, Beijing, China) in this study. To coat the stent surface with VEGF 121 -transfected HUVECs or nontransfected cells, stents were coated with glutin (0.4%) and poly-lysine (10 g/mL) using an ultrasonic spraying process, followed by radiation sterilization with ultraviolet light. Cells were detached from flasks by mild trypsinization (0.25% trypsin for 2-3 minutes at 37°C, followed by neutralizing trypsin with FCS). Detached cells (ϳ10 5 cells/mL) were resuspended in serumfree media. The stent was submerged into the medium containing resuspended cells in an organic glass tube mounted to a custom-built rotating device for 6 hours of rotational culture at the speed of 0.4 rpm 17 (Fig 2, a) , followed by another 48 hours of static culture.
To prepare for further characterizations, cells on the stents were fixed by glutaraldehyde, dehydrated by immersion into ethanol with concentration up to 100%, dried specimens with vacuum freeze-drying, mounted dried specimens on scanning electron microscope (SEM) specimen stub and were sputter coated, and then examined using SEM (Fig 2, b and d ). Cells were detected by immunofluorescence microscopy (Fig 2, c and e) . The primary antibody against rabbit VEGF (Boster, China), both the cyanine-labeled secondary goat anti-rabbit IgG antibody (Boster, China) and fluorescein isothiocyanate-labeled secondary goat anti-rabbit IgG antibody (Beyotime, China) were applied for immunofluorescent staining of transfected cells and non-transfected cells.
A homemade extracorporeal circulation system 18 was used to simulate the transfer process and to characterize cell adhesion and cell growth on the modified surface after stenting in vitro (Fig 3, a) . A stent coated with cells was mounted on a balloon, transported to a gel silica flex tubing, expanded and perfused at various shear rates (5, 10, and 15 dynes/cm 2 ) in the flow system for different lengths of time to simulate the planting experiments in vivo. To quantify the amount of cells that remained adherent on the surface of the stents, cells were first detached and suspended by trypsinization at different time point (0 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 96 hours), followed by methyl thiazolyl-tetrazolium assay (Fig 3, b) . Three independent experiments were performed for each treatment for statistical analysis.
Animal experiments. Animal housing and surgical procedures were followed to conform to the Guide for the Chinese Animal Care and Use Committee standards. All in vivo procedures were also performed in accordance with protocols approved by the Animal Ethics Committee of Chongqing University. Twenty-eight male New Zealand white rabbits that were housed in the Animal Laboratory Center in Chongqing Medical University, China, weighing from 1.5 to 2.5 kg were divided into three groups. Group 1 (bare metal stents [BMS] ; n ϭ 9) received bare metal stents; group 2 (glutin/poly-L-lysine coating stents, GPS, n ϭ 9) received glutin/poly-L-lysine coated stents; and group 3 (VEGF 121 -transfected HUVECs-coated stents, VTHS; n ϭ 10) received VEGF 121 -transfected HUVECscoated stents. Group 3 received an immunological tolerance experiment by injecting transfected-cell suspension for 2 weeks and ensured that the rabbits were healthy without immune reactions before the procedure. The cells were injected intravenously. About 1 ϫ 10 5 cells were used in the injection every day. A blood test was used for immune reactions. Rabbits were fed with a normal diet. Rabbits were anesthetized by administering ketamine (50 mg/kg) intramuscularly and sodium pentobarbital (30 mg/kg) intravenously. A 5F introducer sheath was positioned in the right femoral artery under surgical exposure. Heparin sodium (200 IU/kg) was intra-arterially injected. All catheters were subsequently introduced through this sheath and advanced to the external iliac artery through a 0.014-inch Balance Middle Weight guidewire (Guidant Corp, St. Paul, Minn). Baseline angiograms of the external iliac arteries were obtained for each rabbit. Abdominal aorta injury was performed using an angioplasty balloon catheter (Clearstream, Ireland) at 10 atm for three times in the 10-second interval manner at the same location. With angiography, prepared stents filled with bare metal stent, glutin/poly-L-lysine-coated stents, and VEGF 121 -transfected HUVECs-coated stents were deployed in the infrare- nal abdominal aorta. The abdominal aorta was injured with an angioplasty balloon (diameter 3 mm, length 3 cm). The position of the stent was located at the same position of the balloon injury, which could be located by the guidewire (there are two radiograph opacity sites on the guidewire). Stents were dilated at 10 atm and taken to ensure that no branches were present in the stent segment. At the level of the balloon dilatation, the diameter of the aorta was 2.8 to 3.0 mm, and the expansion ratio of the aorta was between 1.2 and 1.3. Predeployment and postdeployment digital subtraction angiography was recorded. Rabbits were fed a normal diet after the intervention.
One rabbit was killed immediately for the excision of the aortic segment containing the stent after stent planting to test the cell's reservation. The other rabbits were killed at week 1, week 4, and week 12 time points (n ϭ 3, at each time point of each group). Aortic specimens were excised transversely into two parts. One was fixed in 4% paraformaldehyde and then embedded in light-cured resin through toluidine blue stain for pathology organization analysis. The other was fixed in 0.25% glutaraldehyde for 12 to 16 hours for SEM and morphologic analysis of intima surface.
Morphometric analysis was performed with a computerized digital image analysis system by an independent observer blinded to the study groups. Histomorphometric analysis of each section included vessel area (mm 2 ), internal elastic lamina (IEL) area (mm 2 ), lumen area (mm 2 ), neointima area (mm 2 ), and the neointima thickness (mm) by ImageTool (version 2.0; UTHSCSA). The percentage of stenosis was calculated using the following equation:
Statistical analysis. All statistical analyses were performed with SPSS (version 11.0; SPSS Inc, Chicago, Ill). All data are presented as mean Ϯ SD. Comparisons between group means were determined by t test. Probability values of P Ͻ .05 was considered as significant, and P Ͻ .01 was highly significant.
RESULTS

Identification of HUVECs.
HUVECs were identified in terms of the morphology (Fig 1, a) , immunohistochemistry of CD31 (Fig 1, b) . Fig 1, a shows that the shape of the cells seemed to be polygons and they stretched on the plates. A positive immunohistochemistry staining of CD31 was found, as indicated by cell-edged brown circles representing the expression of CD31 in cellular membranes. Therefore, the characteristics of cultured cells were consistent with those of HUVECs.
Transfection with VEGF 121 to HUVECs. After the transfection with VEGF 121 to HUVECs, transfected cells were observed under an inverted microscope. Based on the results of Western blot analysis, the expression of VEGF in the VEGF 121 -transfected group was higher than that in the nontransfected group and pCD 2 transfected group (Fig 1, c) . Results from RT-PCR clearly showed that the gene of VEGF 121 was detected in transfected HUVECs (Fig 1, d) . Immunohistochemistry studies showed significantly increased expression of VEGF in transfected cells (Fig  1, f) ; whereas normal rounded nontransfected cells exhibited little expression of VEGF (Fig 1, e) .
Transfection with VEGF 121 promoted cell growth and adhesion on stents in vitro. VEGF 121 -transfected HUVECs and nontransfected HUVECs were seeded on stents and were observed by SEM. Although seeding of transfected cells achieved a high fraction of cell coverage on the stent surface, non-transfected cells exhibited a rounded morphology and seemed low cell coverage on the stent in the same culture condition (Fig 2, b and d) . Results from immunofluorescence microscopy also demonstrated that Ͼ90% cell coverage on the stent surface was accomplished with VEGF 121 -transfected HUVECs (Fig 2, c and  e) , whereas using nontransfected cells exhibits less cell coverage on stents. Cell adhesions on the surface of the stents were also detected by fluorescence microscopy of VEGF. Red fluorescence indicated that the expression of VEGF in gene-transfected cells was higher than that in nontransfected cells (Fig 2, c and e) . Due to the low cell A, B, and C, 50ϫ; a and b, 1kϫ, c, 500ϫ) . coverage on the stent surface accomplished with nontransfected cells, we chose to focus on VEGF 121 -transfected HUVECs for further in vitro study using the flow system and in vivo study using the rabbit abdominal aorta model.
The stents coated with transfected cells were expanded by a balloon in vitro and subjected to flow shear stresses at 5, 10, and 15 dyn/cm 2 in the flow system for various durations. In this experiment, the amount of live cells was quantified by methyl thiazolyl-tetrazolium assay. Results from experiments with stents studied in the flow system showed that a detectable amount of cells was flushed off from the stents in the first 6 hours, which increased with increasing shear stress. After 6 hours, the population of cells increased, and cell proliferation was observed at three levels of different shear stresses. A more rapid cell proliferation was observed at 5 dyn/cm 2 of shear stress, implicating the role of shear stress in both adhesion and growth of cells on the stent surface (Fig 3, b) . VEGF 121 -transfected HUVECs in rabbit abdominal aorta model. Three rabbits died because the vessel was broken before the stent. One died during the procedure of stent implantation. Twenty-eight stents (9 BMS, 9 GPS, and 10 VTHS) were deployed in the abdominal arteries of rabbits. All rabbits survived for the entire study period (after 1 week, 4 weeks, and 12 weeks). Rabbits were then killed for histomorphometric, histopathologic analysis, and the evaluation of endothelial regeneration. Angiograms obtained immediately after stent implantation and before euthanasia showed that all deployment procedures were successful and that all the stents were dilated. A VTHS was implanted into rabbit artery and taken out for SEM detection after 6 hours to detect the cell reservation in vivo (Fig 3, c and d) . Numerable cells adhered on the surface of stents after implanting (Fig 3, d) . Figs 4-6 shows the re-endothelialization areas on the stents. Results showed that VTHS was almost completely covered with cells after stent implantation for 1 week (Fig 4, C/c) , Fig A/a) , glutin/poly-L-lysine-coated stents (GPS , Fig B/b) , vascular endothelial growth factor (VEGF) 121 -transfected human umbilical vein endothelial cells, and (HUVECs)-coated stent (VTHS , Fig C/c) after implantation for 4 weeks (A, B, and C, 50ϫ; a, b, and c, 1kϫ) . Fig A/a) , glutin/poly-L-lysine-coated stents (GPS, Fig B/b) , vascular endothelial growth factor (VEGF) 121 -transfected human umbilical vein endothelial cells, and (HUVECs)-coated stent (VTHS, Fig C/c) after implantation for 12 weeks (A, B, and C, 50ϫ; a, b, and c, 1kϫ) .
where large numbers of platelets and red cells covering the non-endothelialized areas of BMS (Fig 4, A/a) and GPS (Fig 4, B/b ) at 1 week. BMS (Fig 5, A/a) and GPS (Fig 5,  B/b) were covered at 4 weeks, and the surface of HUVECscoated stent was almost the same as the surface at 1 week (Fig 5, C/c) . The morphology of newly covered cells on the surface of VTHS had little difference with various implantation periods. After implantation of 12 weeks, a monolayer of cells was not found (Fig 6, A/a) , and fragile neointima was found on the surface of GPS (Fig 6, B/b) and BMS (Fig 6, C/c) . 
DISCUSSION
Re-endothelialization had been reported to occur within 4 weeks in rabbit external iliac vessels after stent implantation. 20, 21 However, this process may require significantly longer time (Ͼ12 weeks) in humans. VEGF 121 accelerates endothelial repair by stimulating migration and proliferation of ECs. Results reported by Hedman et al 22 indicated that catheter-mediated intracoronary gene transfer of VEGF was safe and well tolerated to prevent ISR. The treatment did not affect the incidence of postangioplasty restenosis, whereas a significant improvement was observed in myocardial perfusion in the VEGF-Adv-treated patients. Preclinical proangiogenic VEGF studies and anti-VEGF studies have shown that the disturbance of vascular homeostasis by blocking VEGF-A may lead to endothelial dysfunction and adverse vascular effects. 23 Although VEGF therapy has been proven to be of tremendous potential, the preclinical results obtained in animal experiments have not yet been translated into clinical success. The challenge focuses on the complication caused by the carrying agent. Therefore, ECs were proposed here as the perfect carrying agent of VEGF in terms of their histocompatibility and blood compatibility. In this study, HUVECs transfected with VEGF were found to promote endothelialization in vitro, whereas nontransfected ECs seemed to have low recovery ability, and their growth rate dramatically dropped as compared to that of transfected cells. As supported by results from our immunohistochemistry study of VEGF, VEGF 121 -transfected cells expressed VEGF protein, which may maintain local concentration of the growth factor around the stent, thereby enhancing the healing process.
On the other hand, the existence of VEGF may promote the immunosuppression. 24 Injecting and implanting transfected cells improved the VEGF level in the serum, which may play an important role in the cell retention on the stent surface. Hence, nontransfected HUVECs were not used for further studies in the flow system and animal experiments, due to their slow growth, low surface coverage, and immunological rejection. In this study, we seeded VEGF 121 -transfected HUVECs on the surface of metal stents before implantation. There are two preponderances for implantation of VEGF 121 -transfected HUVECs-coated stents: VEGF expression through stable transfection promotes proliferation of ECs and shortens the duration of the cell seeding and coating cells protects vessel wall integrity from the metal stent after implantation.
The rotational culture model was used in this study. The rotational ECs seeding had been used in several studies 25, 26 because many three-dimensional cell material constructs favor dynamic culture conditions. Dynamic culture conditions are frequently applied for cell seeding in the vascular grafts such as polymer materials. 27 However, they are rarely used in endovascular stents. In this study, a rotational device was used for cell seeding on stents and a high surface coverage and cell proliferation of VEGF 121 -transfected HUVECs on both the inner and outer surfaces of stents were achieved.
However, the role of VEGF in neointima formation and ISR remains to be fully elucidated. 28, 29 For example, the presence of transfected HUVECs and the VEGF expression must be traced after stent deployment at different time courses. Chromosome analyses are required for identifying if HUVECs are allogenic cells for rabbits or not. The results thus obtained would identify and verify whether coated HUVEC disappeared or not and which cells are proliferated and migrated to the area of implantation. Such information will help elucidate the mechanism of how coating VEGF-transfected human endothelial cells on stents promotes re-endothelization and inhibits ISR.
In conclusion, after 12 weeks of stent implantation, VEGF 121 -transfected HUVECs-coated stents showed reduced neointima area and stenosis as compared with bare metal stents and glutin/poly-L-lysine-coated stents. Our results, collected from both in vitro and in vivo studies, suggested that VEGF 121 -transfected HUVECs-coated stents could be a new therapeutic strategy to reduce in-stent neointima formation because no evidence of either systemic or local adverse effects was observed in rabbits. More studies are required to validate this therapeutic strategy, for example, the examination of possibly long-term complications introduced by transfected cells in vivo. 
